Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Cancer: early-phase trial registry
147 of 338 indexed Ovarian Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #20 of 28,707 conditions by registered trial count.
338 US clinical trials · 147 currently recruiting · #20 of 28,707 conditions by registered trial count
Ovarian Cancer: 338 US clinical trials tracked, 147 recruiting.
Ovarian Cancer is the subject of 338 registered US clinical trials on ClinicalTrials.gov, 147 of them currently open to new participants. 28 are in Phase 3-4 (later-stage) and 230 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 31 of these trials.
Enrollment posture brief
Registry condition ovarian-cancer
OPEN 147 | RECR 43% | LATE 28 | EARLY 230 | RANK #20 | SPON 31
Volume-matched condition peers
Nearest open-share peer: Cigarette Smoking (43% recruiting · 46 trials)
Ovarian Cancer lists 147 open slots (43% of 338 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian Cancer is recruiting above its size-band peers.
147 of 338 indexed trials (43.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ovarian Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 31 of 338 trials (9.2%). 186 distinct sponsors appear on at least one study for this condition label.
-
Typical Ovarian Cancer enrolment sits around 86 participants.
Median target enrolment is 86 among the 323 trials that report a genuine target (sentinel values excluded). 172 of those (53.3%) plan for fewer than 100 participants.
-
Ovarian Cancer research is mostly interventional.
297 interventional and 41 observational studies make up this index (87.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
338 total, page 3 of 7
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics
NCT07189871
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
National Cancer Institute (NCI)
NCT04847063
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Canadian Cancer Trials Group
NCT04918186
Clinical Pre-screening Protocol for Ovarian Cancer
Allarity Therapeutics
NCT03877796
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Compugen
NCT06888921
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Icahn School of Medicine at Mount Sinai
NCT06040970
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT06580002
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
NCT05922930
Gonadal Dysgenesis Tissue Cryopreservation for Fertility Preservation
University of Colorado, Denver
NCT06518746
Healthy Volunteers Study
Abramson Cancer Center at Penn Medicine
NCT06962059
Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
Stanford University
NCT06646627
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
NCT05877599
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
NCT05568680
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University
NCT05983276
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
M.D. Anderson Cancer Center
NCT06545604
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
NCT04038619
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Hefei TG ImmunoPharma Co.
NCT05746897
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
NCT06971744
The Better, Harder, Faster, Stronger Study
Wake Forest University Health Sciences
NCT07220512
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Memorial Sloan Kettering Cancer Center
NCT05429970
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
M.D. Anderson Cancer Center
NCT05636111
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
NCT05071937
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
Tyler J Curiel
NCT06815497
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
NCT06342986
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06677190
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Sarah K. Lynam MD
NCT05113368
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
M.D. Anderson Cancer Center
NCT05123807
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Imunon
NCT05739981
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Elizabeth Stover, MD, PhD
NCT06964009
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Dana-Farber Cancer Institute
NCT04997096
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Outpace Bio
NCT07030907
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
NCT06305299
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Carevive Systems
NCT05974150
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT07447050
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Nerviano Medical Sciences
NCT06930755
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
NCT06412510
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
University of Alabama at Birmingham
NCT05952453
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
NCT04701645
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
NCT06083844
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
University of Colorado, Denver
NCT06430541
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
University of Wisconsin, Madison
NCT07125209
Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Theolytics Limited
NCT07211659
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
NCT06321484
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05316129
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Radiopharm Theranostics
NCT05799274
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
PhotonPharma
NCT06366490
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT00579514
Clinical Significance of Germline BRCA Mutations
Memorial Sloan Kettering Cancer Center
NCT00579488
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Merck Sharp & Dohme
NCT03740165
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 143 |
| Phase 2 | 87 |
| Phase 3 | 25 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian Cancer page
338 registered trials, 147 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 147 Ovarian Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Ovarian Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Cancer condition card totals 338 registered trials; most-linked intervention Bevacizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.